Al-Aly Z.,Bowe B.,Xie Y. .2022 .Long COVID after breakthrough SARS-CoV-2 infection. Nature Medicine, 28(7) : 1461-1467.
Arumugham V. B.,Rayi A. .2023 .Intravenous Immunoglobulin (IVIG). nlm.nih.gov/pubmed/32119333, : .
Ayoubkhani D.,Bosworth M. L.,King S.,Pouwels K. B.,Glickman M.,Nafilyan V.,Zaccardi F.,Khunti K.,Alwan N. A.,Walker A. S. .2022 .Risk of Long COVID in People Infected With Severe Acute Respiratory Syndrome Coronavirus 2 After 2 Doses of a Coronavirus Disease 2019 Vaccine: Community-Based, Matched Cohort Study. Open Forum Infectious Diseases, 9(9) : .
Ballering A,van Zon S. K. R.,Rosmalen T. C.,J. G. M. T. C. .2022 .Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. The Lancet, 6736(22) : 01214-4.
Bull-Otterson L.,Baca S.,Saydah S.,Boehmer T. K.,Adjei S.,Gray S.,Harris A. M.,States A. M. .2021 .. MMWR. Morbidity and Mortality Weekly Report, 71(21) : 713-717.
Burks A. W.,Sampson H. A.,Buckley R. H. .1986 .Anaphylactic Reactions after Gamma Globulin Administration in Patients with Hypogammaglobulinemia. New England Journal of Medicine, 314(9) : 560-564.
Burnouf T.,Gathof B.,Bloch E. M.,Bazin V.,Patidar G. K.,Rastvorceva R. M. G.,Oreh A.,Goel R.,Rahimi-Levene N.,Hindawi S.,Al-Riyami A. Z.,So-Osman C. .2022 .Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2. , 06(3) : 125-132.
Castanares-Zapatero D.,Chalon P.,Kohn L.,Dauvrin M.,Detollenaere J.,Primus-de Jong C.,Cleemput I.,K. I. .2022 .Pathophysiology and mechanism of long COVID: a comprehensive review. Annals of Medicine, 20769(1) : 1473-1487.
Ceban F.,Ling S.,Lui L. M. W.,Lee Y.,Gill H.,Teopiz K. M.,Rodrigues N. B.,Subramaniapillai M.,Vincenzo Di,Cao J. D.,Lin B.,Mansur K.,Ho R. B.,Rosenblat R. C.,Miskowiak J. D.,Vinberg K. W.,Maletic M.,McIntyre V.,R. S. V.,Brain V. .2021 .Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis.. , 12 : 93-135.
Dalakas M. C. .2021 .. Update on Intravenous Immunoglobulin in Neurology: Modulating Neuroautoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy. Neurotherapeutics, 18(4) : 2397-2418.
Davis H. E.,Assaf G. S.,McCorkell L.,Wei H.,Low R. J.,Redfield Y.,Austin S.,Akrami J. P.,A. J. P. .2021 .Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine, 10101 : 9.
Ephrem A.,Misra N.,Hassan G.,Dasgupta S.,Delignat S.,Van Huyen S.,J.-P. D. S.,Chamat S.,Prost F.,Lacroix-Desmazes S.,Kavery S. V.,Kazatchkine M. D. .2005 .Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin. Clinical and Experimental Medicine, 5(4) : 135-140.
Ewing A. G.,Joffe D.,Blitshteyn S.,Brooks A. E. S.,Wist J.,Bar-Yam Y.,Bilodeau S.,Curtin J.,Duncan R.,Faghy M.,Galland L.,Pretorius E.,Salamon S.,Buonsenso D.,Hastie C.,Kane B.,Khan M. A.,Lal A.,Lau D.,J. D. .2025 .Long COVID clinical evaluation, research and impact on society: a global expert consensus. Annals of Clinical Microbiology and Antimicrobials, 24(1) : .
. .Effectiveness of IVIG in treating Long COVID infection 27. , : .
Galeotti C.,Kaveri S. V,Bayry J. .2017 .IVIGmediated effector functions in autoimmune and inflammatory diseases. International Immunology, 29(11) : 491-498.
Gavrilova N.,Kamaeva E.,Ignatova M.,Ryabkova V.,Lukashenko M.,Soprun L.,Churilov L. P.,Shoenfeld Y. .2022 .Intravenouse immunoglobuline in dysautonomia. Clinical Immunology, 240 : .
Geriak M.,McGrosso D.,Gonzalez D. J.,Dehner M.,Sakoulas G.,Hypoxia Induced .2022 .Case Series of Successful Intravenous Immunoglobulin (IVIG) Treatment in 4 Pregnant Patients with Severe COVID-19-. American Journal of Case Reports, 23 : .
Glynne P.,Tahmasebi N.,Gant V.,Gupta R. . .(2022). Long COVID following Mild SARS-CoV-2 Infection: Characteristic T Cell Alterations and Response to Antihistamines. Journal of Investigative Medicine, 70(1) : 002051-67.
Goddard E. A. .2008 .Intravenous immunoglobulin : review article. Current Allergy & Clinical Immunology, 21(1) : 26-31.
Jordan S. C.,Toyoda M.,Kahwaji J.,Vo A. A. .2010 .Clinical Aspects of Intravenous Immunoglobulin Use in Solid Organ Transplant Recipients. American Journal of Transplantation, 03400(2) : 6143-202.
Jordan S. C.,Toyoda M.,Vo A. A. .2009 .Intravenous Immunoglobulin a Natural Regulator of Immunity and Inflammation. , 88(1) : 1-6.
Junghans R. P.,Anderson C. L. .1996 .The protection receptor for IgG catabolism is the beta2- microglobulin-containing neonatal intestinal transport receptor. Proceedings of the National Academy of Sciences, 93(11) : 5512-5516.
Justiz-Vaillant A.,Soodeen S.,Asin-Milan O.,MoralesEsquivel J.,Arozarena-Fundora R. .2025 .Efficacy of Intravenous Immunoglobulins and Other Immunotherapies in Neurological Disorders and Immunological Mechanisms Involved. , 5(2) : .
Kaur M. N.,Arnold D. M.,Heddle N. M.,Cook R. J.,Hsia C.,Blostein M.,Jamula E.,Sholzberg M.,Lin Y.,Kassis J.,Larratt L.,Tinmouth A.,Carruthers J.,Li N.,Liu Y.,Xie F. .2022 .Costeffectiveness of eltrombopag vs intravenous. , : .
Albar . .immunoglobulin for the perioperative management of immune thrombocytopenia. Blood Advances, 6(3) : 785-792.
Kedor C.,Freitag L.,Wittke K.,Hanitsch L. G.,Zoller T.,Steinbeis F.,Haffke M.,Rudolf G.,Heidecker B.,Bobbert T.,Spranger J.,Volk J.,-D. J.,Skurk C.,Konietschke F.,Paul F.,Behrends U.,Bellmann-Strobl J.,Scheibenbogen C. .2022 .A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity. Nature Communications, 13(1) : .
Kenny G.,Townsend L.,Savinelli S.,Mallon P. W. G. .2023 .Long COVID: Clinical characteristics, proposed pathogenesis and potential therapeutic targets. Frontiers in Molecular Biosciences, 10 : .
Kerr J.,Quinti I.,Eibl M.,Chapel H.,Sewell W. A. C.,Salama W. A. C.,van Schaik I. N.,Kuijpers T. W.,Peter H.-H. .2014 .Is Dosing of Therapeutic Immunoglobulins Optimal? A Review of a Three-Decade Long Debate in Europe. Frontiers in Immunology, 5. , : .
Klein J.,Wood J.,Jaycox J. R.,Dhodapkar R. M.,Lu P.,Gehlhausen J. R.,Tabachnikova A.,Greene K.,Tabacof L.,Malik A. A.,Silva Monteiro V.,Silva J.,Kamath K.,Zhang M.,Dhal A.,Ott I. M.,Valle G.,Peña-Hernández M.,Mao T.,Iwasaki A. .2023 .Distinguishing features of long COVID identified through immune profiling. Nature, 623(7985) : 139-148.
Krause I.,Wu R.,Sherer Y.,Patanik M.,Peter J. B.,Shoenfeld Y. .2002 .In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations - a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases*. Transfusion Medicine, 00360(2) : 3148-139.
Larsen N. W.,Stiles L. E.,Shaik R.,Schneider L.,Muppidi S.,Tsui C. T.,Geng L. N.,Bonilla H.,Miglis M. G. .2022 .Characterization of autonomic symptom burden in long COVID: A global survey of 2,314 adults. , 10 : .
Leslie J. Vaughan .2014 .Immune globulin and pregnancy. , : .
Halpern Luke . .(2024, August 2). Intravenous immunoglobulin effective in achieving viral. , : .
. .com/view/intrav enous-immunoglobulin-effective-in-achieving-viralclearance-neutralizing-several-sars-cov-2-variants. Pharmacy Times - Pharmacy Practice News and Expert Insights, : .
Lünemann J. D.,Nimmerjahn F.,Dalakas M. C. .2014 .Intravenous immunoglobulin in neurologymode of action and clinical efficacy. Nature Reviews Neurology, 11(2) : 80-89.
Lünemann J. D.,Quast I.,Dalakas M. C. .2016 .Efficacy of Intravenous Immunoglobulin in Neurological Diseases. , 13(1) : 34-46.
Manaresi E.,Gallinella G. .2019 .Advances in the Development of Antiviral Strategies against Parvovirus B19. , 11(7) : .
Mancini D. M.,Brunjes D. L.,Lala A.,Trivieri M. G.,Contreras J. P.,Natelson B. H. .2021 .Use of Cardiopulmonary Stress Testing for Patients With Unexplained Dyspnea PostCoronavirus Disease. JACC: Heart Failure, 10(12) : 927-937.
McDuff K.,Brown D. A.,Gross D. P.,Faghy M. A.,Davenport T. E.,Audette J.,Bassi L.,Bull M.,Cobbing S. E.,Décary S.,Flynn A.,Jeyes F.,Kaup C.,Martin M.,Ngeh E.,Putrino D.,Saravia A.,Shiloff-Rogers A.,Skiffington A.,… O'Brien K. K. .2025 .Priorities for Research, Education, Clinical Practice, and Policy From the Long COVID Physio International Forum. Cardiopulmonary Physical Therapy Journal, 36(2) : 000000000000027-9.
Mielke O.,Bril V.,Cornblath D. R.,Lawo N.,Hartung H.,Lewis R. A.,Merkies I. S. J.,Sobue G.,Durn B.,Shebl A.,Schaik I. N. .2019 .Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneuropathy And Treatment with Hizentra study. Journal of the Peripheral Nervous System, 24(1) : 72-79.
Montalvo M.,Nallapaneni P.,Hassan S.,Nurko S.,Pittock S. J.,Khlevner J. .2022 .Autoimmune gastrointestinal dysmotility following SARS‐CoV‐2 infection successfully treated with intravenous immunoglobulin. Neurogastroenterology & Motility, 34(7) : .
Morse B. A.,Motovilov K.,Michael Brode W.,Michael Tee F.,Melamed E. .2025 .A review of intravenous immunoglobulin in the treatment of neuroimmune conditions, acute COVID-19 infection,. , : .
Albar .2024 .and post-acute sequelae of COVID-19 Syndrome. , 10 : 725-738.
Mouthon L.,Guillevin L.,Tellier Z. .2004 .Intravenous immunoglobulins in autoimmune- or parvovirus B19-mediated pure red-cell aplasia. Autoimmunity Reviews, 10(5) : 264-269.
Mouthon L.,Lortholary O. .2003 .Intravenous immunoglobulins in infectious diseases: where do we stand?. Clinical Microbiology and Infection, 00694(5) : 0691-338.
. .-launches-long-covid-clinical-trialsthrough-recover-initiative-openingenrollment#:~:text=RECOVER%20is%20a%20large %2C%20nationwide,than%2024%2C000%20particip ants%20to%20date. National Institutes of Health (NIH), : .
. .-opens-long-covid-trials-evaluatetreatments-autonomic-nervous-system-dysfunction. (2024, March, 12 : .
Ogawa S. .2014 .. Nihon Rinsho, 72(9) : 1578-1584.
Overton P. M.,Shalet N.,Somers F.,Allen J. A. .2021 .Patient Preferences for Subcutaneous versus Intravenous Administration of Treatment for Chronic Immune System Disorders: A Systematic Review. Patient Preference and Adherence, 15 : 811-834.
Parker W. H.,Moudgil R.,Tonelli R. G.,Mayuga A. R.,Singh K. A.,T. K. K. A. .2021 .COVID-19 and postural tachycardia syndrome: a case series. European Heart Journal - Case Reports, 5(12) : .
Perez E. E.,Orange J. S.,Bonilla F.,Chinen J.,Chinn I. K.,Dorsey M.,El-Gamal Y.,Harville T. O.,Hossny E.,Mazer B.,Nelson R.,Secord E.,Jordan S. C.,Stiehm E. R.,Vo A. A.,Ballow M. .2016 .Update on the use of immunoglobulin in human disease: A review of evidence. Journal of Allergy and Clinical Immunology, 09(3) : S1-S46.
Perricone C.,Triggianese P.,Bartoloni E.,Cafaro G.,Bonifacio A. F.,Bursi R.,Perricone R.,Gerli R. .2020 .The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. Journal of Autoimmunity, 111 : .
Kent S. J.,Dore G. J.,Kelleher A. D.,Matthews G. V. .2022 .Immunological dysfunction persists for 8 months following initial mild-tomoderate SARS-CoV-2 infection. Nature Immunology, 23(2) : 210-216.
Planitzer C. B.,Farcet M. R.,Schiff R. I.,Ochs H. D.,Kreil T. R. .2011 .Neutralization of different echovirus serotypes by individual lots of intravenous immunoglobulin. Journal of Medical Virology, 83(2) : 305-310.
Proal A. D.,VanElzakker A. D. .2021 .(2021). Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. , 12 : .
Pyzik M.,Kozicky L. K.,Gandhi A. K.,Blumberg R. S. .2023 .The therapeutic age of the neonatal Fc receptor. Nature Reviews Immunology, 23(7) : 415-432.
Rachid R.,Castells M.,Cunningham-Rundles C.,Bonilla F. A. .2011 .Association of anti-IgA antibodies with adverse reactions to γ-globulin infusion. Journal of Allergy and Clinical Immunology, 01(1) : 228-230.
Ramasamy A.,Wang C.,Brode W. M.,VerduzcoGutierrez M.,Melamed E. .2023 .Immunologic and Autoimmune-Related Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Physical Medicine and Rehabilitation Clinics of North America, 04(3) : 623-642.
Randhawa P.,Pastrana D. V.,Zeng G.,Huang Y.,Shapiro R.,Sood P.,Puttarajappa C.,Berger M.,Hariharan S.,Buck C. B. .2015 .Commercially Available Immunoglobulins Contain Virus Neutralizing Antibodies Against All Major Genotypes of Polyomavirus BK. American Journal of Transplantation, 15(4) : 1014-1020.
Reznik S.,Tiwari A.,Ashby C. .2021 .Intravenous immunoglobulin: A potential treatment for the postacute sequelae of SARS-Cov-2 infection? Bosnian Journal of Basic Medical Sciences. , : .
Rodriguez B.,Hoepner R.,Salmen A.,Kamber N.,Z'Graggen W. J. .2021 .Immunomodulatory treatment in postural tachycardia syndrome: A case series. European Journal of Neurology, 28(5) : 1692-1697.
Schwab I.,Nimmerjahn F. .2013 .Intravenous immunoglobulin therapy: how does IgG modulate the immune system. Nature Reviews Immunology, 13(3) : 176.
Albar . .. , 189 : .
Seite J.-F.,Shoenfeld Y.,Youinou P.,Hillion S. .2008 .What is the contents of the magic draft IVIg? Autoimmunity Reviews. , 04(6) : 435-439.
Su Y.,Yuan D.,Chen D. G.,Ng R. H.,Wang K.,Choi J.,Li S.,Hong S.,Xie J.,Kornilov S. A.,Scherler K.,Pavlovitch-Bedzyk A. J.,Dong S.,Lausted C.,Lee I.,Fallen S.,Dai C. L.,Baloni P.,Heath J. R. .2022 .Multiple early factors anticipate post-acute COVID-19 sequelae. , 01(5) : 881-895.
Thompson J. S.,Thornton A. C.,Ainger T.,Garvy B. A. .2022 .Long-term high-dose immunoglobulin successfully treats Long COVID patients with pulmonary, neurologic, and cardiologic symptoms. Frontiers in Immunology, 13 : .
Wallukat G.,Hohberger B.,Fürst K.,Schulze-Rothe J.,Wallukat S.,Hönicke A.,Müller A.-S.,J. A.-S. .2021 .Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. Journal of Translational Autoimmunity, 4 : .
Xie Y.,Al-Aly Z. .2022 .Risks and burdens of incident diabetes in long COVID: a cohort study. The Lancet Diabetes & Endocrinology, 8587(22) : 00044-4.
Xie Y.,Xu E.,Bowe B.,Al-Aly Z. .2022 .Long-term cardiovascular outcomes of COVID-19. , 28(3) : 583-590.
Younger D. S. .2021 .Post-acute sequelae of SARSCoV-2 infection (PASC): peripheral, autonomic, and central nervous system features in a child. Neurological Sciences, 42(10) : 3959-3963.